Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes
Information source: Novo Nordisk A/S
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes; Diabetes Mellitus, Type 2
Intervention: repaglinide (Drug); glyburide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Novo Nordisk A/S Official(s) and/or principal investigator(s): Paula Hale, Study Director, Affiliation: Novo Nordisk A/S
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to
compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.
Clinical Details
Official title: Repaglinide Versus Glyburide: Comparitive Effect on Postprandial Lipemia: An Open-labeled, Randomized, Parallel Group Study in Patients With Type 2 Diabetes
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Triglyceride levels post standardised fat tolerance test
Secondary outcome: Incidence of hypoglycemic episodesChange in HbA1c (glycosylated haemoglobin A1c) Change in FPG (fasting plasma glucose)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Newly diagnosed patients with type 2 diabetes currently treated with diet and
exercise alone (HbA1c below 10%)
- Subjects with type 2 diabetes treated with sulphonylurea (HbA1c below 8. 5%)
- Males or non-pregnant, non-lactating females
- Subjects should have normal renal function
Exclusion Criteria:
- Type 1 or other specific causes of diabetes
- Marked symptomatic diabetes
- Uncontrolled treated/untreated hypertension
- Known or suspected allergy to the trial products or related products
Locations and Contacts
Novo Nordisk Clinical Trial Call Center, Houston, Texas 77030, United States
Additional Information
Clinical Trials at Novo Nordisk
Starting date: November 2001
Last updated: August 30, 2012
|